Project Grant R01CA302815
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $515K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA 22904, USA
Similar Awards
- The National Cancer Institute awarded the University of Virginia $484,387 on May 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel statistical methods for the design, analysis, and implementation of enzyme-linked immunospot (ELISPOT) experiments. The project addresses inconsistency in how ELISPOT assay data—used to quantify cytokine-secreting cells in basic, clinical, and translational immunotherapy studies—are analyzed across research settings. Current practice...
- The National Cancer Institute awarded the University of Virginia $529,456 on August 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate how inhibition of the ufmylation protein pathway enhances anti-tumor immunity and converts immunologically cold tumors into responsive ones. The project uses genetic and chemical inhibitors of the UBA5 protein—a key component of the ufmylation posttranslational modification pathway—to test whether ufmylation inhibition reduces...
- The National Cancer Institute awarded the University of Virginia $404,349 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on April 1, 2026, to develop and validate quantitative magnetic resonance imaging methods for measuring macromolecular delivery to brain tumors following focused ultrasound and microbubble treatment. The research addresses the blood-tumor barrier, which limits therapeutic drug delivery to brain metastases and contributes to higher patient mortality...
- The National Cancer Institute awarded Virginia Commonwealth University $129,194 on August 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to expand participation in National Cancer Institute-sponsored clinical trials through leadership development, education, and community partnerships. Keri R. Maher, DO, Medical Director of the Clinical Trials Office at Massey Comprehensive Cancer Center within VCU, will dedicate 25 percent effort to this work. She will implement a formal...
- The National Cancer Institute awarded the University of Virginia $161,500 for cancer cell biology research on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The project develops methods to classify pancreatic ductal adenocarcinoma circulating tumor cells by single-cell deformability. Researchers will create a perfusable co-culture system with cancer-associated fibroblasts to generate pancreatic cancer cells expressing varied epithelial and mesenchymal states under shear...
- The National Cancer Institute awarded $415,257 to the University of Virginia on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a comprehensive intervention addressing financial toxicity among cancer survivors and caregivers. The award funds a two-year project (July 1, 2026 through June 30, 2028) performed in Charlottesville, Virginia. The intervention will address all domains of financial toxicity—material burden, psychosocial distress, and coping...
- The National Cancer Institute awarded the University of Virginia $669,910 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to optimize pharmacist-led tobacco treatment for individuals who smoke and are not ready to make a quit attempt in federally qualified health centers. The project, titled "Optimizing Pharmacist-Led Tobacco Treatment for Individuals Who Smoke and Are Not Ready to Make a Quit Attempt in Federally Qualified Health Centers,"...
- The National Cancer Institute awarded Virginia Commonwealth University $511,930 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify molecular determinants of response and resistance to TROP2-targeted antibody-drug conjugates and develop strategies to enhance therapeutic efficacy in triple-negative breast cancer and pancreatic adenocarcinoma. The project spans five years through July 31, 2031, with work performed in Richmond, Virginia. The research...
- The National Cancer Institute awarded Virginia Commonwealth University $399,187 under the Cancer Treatment Research program (CFDA 93.395) on May 7, 2026, to develop glycosaminoglycans-based theragnostic approaches for treating platinum-resistant gynecological malignancies, specifically ovarian cancer. The project supports exploratory and developmental research on how sulfated glycosaminoglycans, including heparan sulfate and chondroitin sulfate, mediate tumor uptake of platinum-based...
- The National Cancer Institute awarded the University of Virginia $192,887 on May 8, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on sphingolipid-guided stratification and therapeutic opportunities in acute myeloid leukemia. The project investigates sphingolipid metabolism as a mechanism to improve acute myeloid leukemia risk classification beyond genomic characterization. Prior work identified two AML patient subtypes distinguished by reciprocal abundance of...